Cellvizio by Mauna Kea Technologies

Cellvizio by Mauna Kea Technologies Cellvizio is the real-time in vivo cellular imaging platform that revolutionizes the way physicians

Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio®, the real-time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real-time, classify indeterminate areas of concern, and guide sur

gical interventions. The Cellvizio platform is used globally across a wide range of medical specialties and is revolutionizing the way physicians diagnose and treat patients — making a transformative change in medicine.

Today is National Cancer Survivors Day, a day to honor the extraordinary resilience of those who have faced cancer and t...
06/07/2026

Today is National Cancer Survivors Day, a day to honor the extraordinary resilience of those who have faced cancer and to recognize the loved ones, caregivers, and clinicians who stand beside them.

At Cellvizio by Mauna Kea Technologies, we are privileged to support the physicians and care teams working every day to improve diagnostic precision so that more patients have a survival story to share. Every advancement in is a step toward more survivors.

To every survivor; we see you, we celebrate you.

An enriching pancreatic cyst nCLE with Workshop at Ramsay Santé, led by Dr. Bertrand Napoléon, uniting expert physicia...
06/05/2026

An enriching pancreatic cyst nCLE with Workshop at Ramsay Santé, led by Dr. Bertrand Napoléon, uniting expert physicians from France, Spain, and Serbia around one goal: better patient outcomes through shared knowledge.

Grateful to have had Drs. Rivallin, Gonzalo López Roldán, and Stanko Petrovic attend, bringing their expertise to life through real-world case discussions and invaluable clinical insights.

Together we're sharing the latest evidence and techniques to effectively classify and risk-stratify pancreatic cysts with Cellvizio, making a profound difference for patients everywhere.

06/04/2026

A new study shines a light on the power of triple healing for IBD patients, meaning histological remission and an intact intestinal barrier in both the ileum and colon.

Triple healing: 0 relapses in 29 patients over 24 months.
Fall short of it: ~33% relapse.

One benchmark, two very different outcomes, and it comes down to what you can actually see. Endoscopy misses it. makes it visible, in real time. Across 5 independent studies, 430+ patients, 5 countries, and a decade of research, the same signal keeps emerging: CLE imaging of the intestinal barrier predicts outcomes conventional tools miss.

Published in UEG Journal. Read in full: https://hubs.la/Q04k4XkW0

The World Gastroenterology Organisation established World Digestive Health Day to raise awareness about digestive health...
05/29/2026

The World Gastroenterology Organisation established World Digestive Health Day to raise awareness about digestive health issues and promote preventative measures. Digestive problems affect millions around the globe, so it’s important to prioritize . As a global medical device company, we’re dedicated to providing solutions to take charge of gut health.

https://hubs.la/Q04gcT8t0

is officially expanding into the United Arab Emirates and Turkey!We’ve obtained key regulatory clearances for in t...
05/26/2026

is officially expanding into the United Arab Emirates and Turkey!

We’ve obtained key regulatory clearances for in these two major markets, already securing our first commercial sale in the UAE for the CellTolerance program. With and food intolerances impacting up to 27% of the population in these markets, our precision diagnostics are ready to make a major impact.

Read the full press release: https://hubs.ly/Q04hytGJ0

05/21/2026

Cellvizio by Mauna Kea Technologies has obtained regulatory clearances for in the United Arab Emirates and Turkey. These approvals open doors to two of the world's most compelling markets for precision diagnostics where and food intolerances affect up to 27% of the population on average, and up to 39% of young adults in the UAE.

Building immediately on these clearances, we confirm our first commercial sale of Cellvizio in the UAE, dedicated specifically to the program. The region's thriving premium private healthcare sector and strong patient purchasing power make it uniquely suited to our commercial strategy.

Read the full press release: https://hubs.ly/Q04hwR6d0

05/20/2026

Cellvizio by Mauna Kea Technologies has obtained regulatory clearances for in the United Arab Emirates and Turkey. These approvals open doors to two of the world's most compelling markets for precision diagnostics where and food intolerances affect up to 27% of the population on average, and up to 39% of young adults in the UAE.

Building immediately on these clearances, we confirm our first commercial sale of Cellvizio in the UAE, dedicated specifically to the program. The region's thriving premium private healthcare sector and strong patient purchasing power make it uniquely suited to our commercial strategy.

Read the full press release: https://hubs.la/Q04hnlVn0

05/19/2026

Crohn’s Disease and Ulcerative Colitis are two chronic inflammatory bowel diseases ( ) that affect millions of people around the world. While not showing any outward signs of their condition, many struggle to get the support and understanding that they need.

To learn how can be superior to conventional severity scoring, visit: https://hubs.la/Q04gcT9k0



Crohn's & Colitis Foundation

05/07/2026

The stakes for early detection have never been higher. For clinicians, the challenge isn't just treating the lesion, it’s navigating the long road to Complete Remission of Intestinal Metaplasia (CRIM).

We can't control the rise of the disease alone, but with advanced imaging, we can control how we find and treat it.

How it works: https://hubs.la/Q04fTYHg0

05/07/2026

offers unprecedented cellular-level visualization, empowering physicians to understand and treat patients with greater precision unlike any other platform available today. This groundbreaking technology is transforming the landscape of healthcare.

Discover Cellvizio's transformative impact: https://hubs.la/Q04fQQpq0

Address

24 Denby Road, Suite 140
Boston, MA
02134

Opening Hours

Monday 8:30am - 5pm
Tuesday 8:30am - 5pm
Wednesday 8:30am - 5pm
Thursday 8:30am - 5pm
Friday 8:30am - 5pm

Website

Alerts

Be the first to know and let us send you an email when Cellvizio by Mauna Kea Technologies posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share